GEFITINIB (IRESSA) INHIBITS THE CYP3A4-MEDIATED FORMATION OF 7-ETHYL-10-(4-AMINO-1-PIPERIDINO)CARBONYLOXYCAMPTOTHECIN BUT ACTIVATES THAT OF 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO]CARBONYLOXYCAMPTOTHECIN FROM IRINOTECAN

Gefitinib (Iressa) is an anticancer drug that selectively inhibits tyrosine kinases of epidermal growth factor receptor. Gefitinib might affect CYP3A4-mediated metabolism, since the drug is a substrate of human CYP3A. In this study, we evaluated the effects of gefitinib on drug metabolism catalyzed by human CYP3A4. The effects of gefitinib on the CYP3A4-mediated formation of NPC (7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin) and that of APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin) from irinotecan were examined with the use of human liver and small intestinal microsomes. Gefitinib inhibited the formation of NPC in liver and small intestinal microsomes. The apparent intrinsic metabolic clearance (CLint) in the presence of 40 μM gefitinib was equivalent to about 26% of control in liver microsomes and 45% of control in small intestinal microsomes. Gefitinib stimulated the formation of APC by CYP3A4. CLint in the presence of 20 μM gefitinib with human liver microsomes was about 1.9 times higher than control. In human small intestinal microsomes, APC formation was enhanced by the addition of gefitinib at concentrations 20 μM or higher. CLint in the presence of 40 μM gefitinib was 2.8 times higher than control. Thus, we discovered that gefitinib inhibited the formation of NPC but stimulated the formation of APC from irinotecan.

[1]  W. Bretz,et al.  Red Marine Algae Lithothamnion calcareum Supports Dental Enamel Mineralization , 2023, Marine drugs.

[2]  G. S. Miles,et al.  Cytochrome P450-dependent metabolism of gefitinib , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  J. Verweij,et al.  Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. , 2004, Journal of the National Cancer Institute.

[4]  Peter J Houghton,et al.  Gefitinib Enhances the Antitumor Activity and Oral Bioavailability of Irinotecan in Mice , 2004, Cancer Research.

[5]  J. Schellens,et al.  Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration. , 2004, Clinical colorectal cancer.

[6]  Jose Cosme,et al.  Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone , 2004, Science.

[7]  R. Pazdur,et al.  United States Food and Drug Administration Drug Approval Summary , 2004, Clinical Cancer Research.

[8]  D. Dunbar,et al.  Characterization of mouse small intestinal cytochrome P450 expression. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[9]  T. Ikenoue,et al.  Inhibitory effects of citrus fruits on cytochrome P450 3A (CYP3A) activity in humans. , 2003, Biological & pharmaceutical bulletin.

[10]  A. Galetin,et al.  Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[11]  Sharon Marsh,et al.  Irinotecan pathway genotype analysis to predict pharmacokinetics. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  A. Galetin,et al.  Quinidine and haloperidol as modifiers of CYP3A4 activity: multisite kinetic model approach. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[13]  T. Tracy,et al.  Atypical kinetic profiles in drug metabolism reactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[14]  K. Gibson,et al.  Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. , 2001, Bioorganic & medicinal chemistry letters.

[15]  A Gouyette,et al.  Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  T. Sakuma,et al.  A novel female-specific member of the CYP3A gene subfamily in the mouse liver. , 2000, Archives of biochemistry and biophysics.

[17]  P. Neuvonen,et al.  The effect of rifampin on the pharmacokinetics of oral and intravenous ondansetron , 1999, Clinical pharmacology and therapeutics.

[18]  R. Labianca,et al.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer , 1998, The Lancet.

[19]  J. Robert,et al.  Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecine] by human hepatic microsomes. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[20]  B. Ring,et al.  Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone. , 1998, Pharmacogenetics.

[21]  M. Fukuoka,et al.  Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Robert,et al.  Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. , 1998, Cancer research.

[23]  A. Akabayashi.  Questions raised over release of side-effects data in Japan , 1997, The Lancet.

[24]  James R. Halpert,et al.  Alanine-scanning Mutagenesis of a Putative Substrate Recognition Site in Human Cytochrome P450 3A4 , 1997, The Journal of Biological Chemistry.

[25]  A. P. Koley,et al.  Differential Mechanisms of Cytochrome P450 Inhibition and Activation by α-Naphthoflavone* , 1997, The Journal of Biological Chemistry.

[26]  F. Guengerich,et al.  Cooperativity in oxidations catalyzed by cytochrome P450 3A4. , 1997, Biochemistry.

[27]  B. K. Park,et al.  Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. , 1996, The Journal of pharmacology and experimental therapeutics.

[28]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[29]  D. Davies,et al.  Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. , 1994, Biochemical pharmacology.

[30]  K. Korzekwa,et al.  Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. , 1994, Biochemistry.

[31]  D. Wortham,et al.  Itraconazole Affects Single‐Dose Terfenadine Pharmacokinetics and Cardiac Repolarization Pharmacodynamics , 1993, Journal of clinical pharmacology.

[32]  D. Wortham,et al.  The effect of fluconazole on the steady‐state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans , 1993, Clinical pharmacology and therapeutics.

[33]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[34]  M. Fukuoka,et al.  Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. , 1991, Journal of the National Cancer Institute.

[35]  E. Johnson,et al.  Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. , 1988, Molecular pharmacology.

[36]  J. Baselga,et al.  Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  L. Wienkers,et al.  Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. , 2001, Advances in Experimental Medicine and Biology.